An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

Summary

Stoke Therapeutics is evaluating the long-term safety \& tolerability of repeated doses of zorevunersen (STK-001) in patients with Dravet syndrome who previously participated in studies of zorevunersen. Change in seizure frequency and overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.

Timeline

Start

2021-01-20

Primary completion

2029-03-31

Completion

2029-03-31

Outcome

Met primary endpoint

release “Zorevunersen has been generally well tolerated across the Phase 1/2a and OLE studies.” stoketherapeutics.com ↗

Publications

• Laux L, Sullivan J, Perry MS, Brunklaus A, Desurkar A, Schreiber JM, Roberts CM, Knupp KG, Wheless JW, Wirrell EC, Ventola P, Wang F, Meena, Lynch J, Parkerson KA, Ticho B, Cross JH; MONARCH, ADMIRAL, SWALLOWTAIL, and LONGWING Study Groups. Zorevunersen in Children and Adolescents with Dravet Syndrome. N Engl J Med. 2026 Mar 5;394(10):969-982. doi: 10.1056/NEJMoa2506295.

Drugs

Indications